Large-cap Health Care company Zoetis has logged a -2.5% change today on a trading volume of 1,272,357. The average volume for the stock is 1,867,709.
Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. Based in Parsippany, United States the company has 13,800 full time employees and a market cap of $89,522,634,752. Zoetis currently offers its equity investors a dividend that yields 0.7% per year.
The company is now trading -9.8% away from its average analyst target price of $216.18 per share. The 11 analysts following the stock have set target prices ranging from $190.0 to $255.0, and on average give Zoetis a rating of buy.
Over the last 52 weeks, ZTS stock has risen 38.5%, which amounts to a 16.0% difference compared to the S&P 500. The stock's 52 week high is $201.92 whereas its 52 week low is $140.76 per share. Based on Zoetis's average net margin growth of 1.4% over the last 6 years, its core business is on track for profitability and its strong stock performance may continue in the long term.
| Date Reported | Total Revenue ($ k) | Net Profit ($ k) | Net Margins (%) | YoY Growth (%) |
|---|---|---|---|---|
| 2023 | 8,371,000 | 2,280,000 | 27 | 3.85 |
| 2022 | 8,080,000 | 2,114,000 | 26 | 0.0 |
| 2021 | 7,776,000 | 2,037,000 | 26 | 4.0 |
| 2020 | 6,675,000 | 1,638,000 | 25 | 4.17 |
| 2019 | 6,260,000 | 1,500,000 | 24 | -4.0 |
| 2018 | 5,825,000 | 1,428,000 | 25 |
